Business
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense AgreementExo-Top Inc. positioned as a strategic U.S. subsidiary supporting manufacturing, clinical advancement and long-term value creation\nTORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based therapies, today announced that its two wholly owned subsidiaries, Exo-Top Inc. (“Exo-Top”) and NurExone Biologic Ltd. (“NurExone Ltd.”), have entered into a sublicense agreement (the “Exo-Top Sublicense”). Under the Exo-Top Sublicense, NurExone Ltd. has granted Exo-Top certain rights under an exclusive worldwide development and commercialization license (the “Tech License”) with Technion Research and Development Foundation Ltd. (“TRDF”) and Ramot, Tel Aviv University’s technology transfer company (“Ramot”), entered into on June 23, 2020, and subsequently amended. The sublicense further establishes Exo-Top’s role in NurExone’s U.S. strategy and is intended to support future manufacturing, development, and commercial activities for naïve exosomes in the U.S. Moreover, the Company believes the Exo-Top Sublicense enhances strategic flexibility in a key market. Dr. Lior Shaltiel, Chief Executive Officer of NurExone, said, “The Exo-Top Sublicense represents an important step in building Exo-Top as a key part of NurExone’s long-term U.S. strategy. By providing Exo-Top with licensed rights, we are aligning our corporate structure with our plans to support future manufacturing, development, and commercialization in North America.” Pursuant to the Tech License, the Company is obligated to pay TRDF certain royalty fees upon reaching Phase II of clinical trials and additional royalties on commercialization. No monetary consideration was paid by Exo-Top to NurExone Ltd. in connection with the Exo-Top Sublicense. Accordingly, the Company does not expect any sublicense fees to be payable to TRDF in connection with the execution of the Exo-Top Sublicense. About Exo-Top Exo-Top is NurExone’s wholly owned U.S. subsidiary. It is being developed to support the Company...